Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant

Table 3 Distribution of patients according to the lack of cytoplasmic programmed cell death protein 1 ligand 1 expression and the clinical and pathological characteristics of breast cancer patients

	The lack of cPDCD1 LG1 in < 20% of the TCs		The lack of cPDCD1 LG1 in ≥ 20% of the TCs		P value
	n	%	n	%
T stage
Тin situ	4	100	0	0	0.0052a
Т1в	9	81.8	2	18.2
Т1с	51	57.3	38	42.7
Т2	16	36.4	28	63.6
N stage
N0	42	51.9	39	48.1	0.24
N1	24	51.1	23	48.9
N2-3	14	62.5	6	37.5
Clinical stage
0	4	100	0	0	0.059
I (IA)	30	56.6	23	43.4
IIA	24	43.6	31	56.4
IIB	8	47.1	9	52.9
IIIA	10	66.7	5	33.3
IIIB	4	100	0	0
Tumor grade
G1	14	87.5	2	12.5	0.0000a
G2	55	63.2	32	36.8
G3	11	24.4	34	75.6
Lymphovascular invasion
Absent	48	57.1	36	42.9	0.39
Present	32	50.0	32	5.0
Perineural invasion
Absent	64	55.7	51	44.3	0.47
Present	16	48.5	17	51.5
Intraductal component
Absent	57	53.3	50	46.7	0.76
Present	23	56.1	18	43.9
Estrogen receptor status
Negative	5	31.3	11	68.7	0.052
Positive	75	56.8	57	43.2
Progesterone receptor status
Negative	21	51.2	20	48.8	0.67
Positive	59	55.1	48	44.9
HER2 status
Negative	73	57.0	55	43.0	0.070
Positive	7	35.0	13	65.0
Molecular biological subtype
Luminal A	42	75.0	14	25.0	0.0011a
Luminal B HER2-	28	42.4	38	57.6
Luminal B HER2+	5	50.0	5	50.0
Nonluminal HER2+	2	20.0	8	80.0
TNBC	3	50.0	3	50.0

^aP < 0.05 was considered statistically significant.

Statistical test: χ². HER2: Human epidermal growth factor receptor 2; TNBC: Triple negative breast cancer; cPDCD1 LG1: Cytoplasmic programmed cell death protein 1 ligand 1; TCs: Tumor cells.